Statement of deviation or variation in the use of proceeds of Rights issue for the Quarter ended 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Ltd has filed its quarterly statement under SEBI LODR Regulation 32 confirming that there is no deviation or variation in the use of proceeds from its Rights Issue, which raised Rs. 4,845.05 Lakhs (allotment date: 21st February 2024). The funds were originally earmarked for five purposes: acquiring equity in Dexceng Healthcare Pvt Ltd to make it a subsidiary (Rs. 1,443.58 Lakhs – fully utilised), repaying/prepaying borrowings (Rs. 588 Lakhs – Rs. 289 Lakhs utilised so far), working capital (Rs. 1,650 Lakhs – fully utilised), general corporate purposes (Rs. 1,138.47 Lakhs – fully utilised), and issue expenses (Rs. 25 Lakhs – fully utilised). The Audit Committee and auditors had no comments, and no monitoring agency was appointed. The filing is a routine regulatory compliance update for the quarter ended 31st December 2025.
This is a routine compliance filing with no negative signal – the company is using rights issue funds as originally promised to shareholders. No impact on stock price is expected; it simply reinforces that capital allocation remains on track.